Innovative adjuvant augments potency of a SARS-CoV-2 subunit vaccine

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

(2022) Wilfredo F. Garcia-Beltran et al.   CELL

A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs

(2022) Zezhong Liu et al.   CELL RESEARCH

Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron

(2022) Juan Manuel Carreño et al.   NATURE

Delivery of STING agonists for adjuvanting subunit vaccines

(2021) Simon Van Herck et al.   ADVANCED DRUG DELIVERY REVIEWS

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells

(2020) Yunlong Cao et al.   CELL

Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses

(2020) Tania Gupta et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

cGAS in action: Expanding roles in immunity and inflammation

(2019) Andrea Ablasser et al.   SCIENCE

Viromimetic STING Agonist‐Loaded Hollow Polymeric Nanoparticles for Safe and Effective Vaccination against Middle East Respiratory Syndrome Coronavirus

(2019) Leon Chien‐Wei Lin et al.   ADVANCED FUNCTIONAL MATERIALS

Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations

(2014) Nadia Jeremiah et al.   JOURNAL OF CLINICAL INVESTIGATION

Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer

(2011) Primo N. Lara et al.   JOURNAL OF CLINICAL ONCOLOGY